v3.25.4
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2025
Dec. 31, 2024
Assets    
Cash and cash equivalents $ 1,142 $ 1,043
Short-term investments 12,454 19,434
Trade accounts receivable, net of allowance for doubtful accounts: 2025—$427; 2024—$438 11,874 11,463
Inventories 10,654 10,851
Current tax assets 3,967 3,314
Other current assets 2,808 4,253
Total current assets 42,898 50,358
Long-term investments 1,621 2,228
Property, plant and equipment, net 19,317 18,393
Identifiable intangible assets, net 53,731 55,411
Goodwill [1] 71,264 68,527
Noncurrent deferred tax assets and other noncurrent tax assets 9,699 8,662
Other noncurrent assets 9,631 9,817
Total assets 208,160 213,396
Liabilities and Equity    
Short-term borrowings, including current portion of long-term debt: 2025—$2,997; 2024—$3,747 3,154 6,946
Trade accounts payable 5,240 5,633
Dividends payable 2,445 2,437
Income taxes payable 3,103 2,910
Accrued compensation and related items 3,610 3,838
Deferred revenues 784 1,511
Other current liabilities 18,648 19,720
Total current liabilities 36,984 42,995
Long-term debt 61,641 57,405
Pension and postretirement benefit obligations 2,041 2,115
Noncurrent deferred tax liabilities 2,401 2,122
Other taxes payable 3,591 6,112
Other noncurrent liabilities 14,725 14,150
Total liabilities 121,385 124,899
Commitments and Contingencies
Common stock, $0.05 par value; 12,000 shares authorized; issued: 2025—9,621; 2024—9,593 481 480
Additional paid-in capital 94,469 93,603
Treasury stock, shares at cost: 2025—3,935; 2024—3,926 (115,015) (114,763)
Retained earnings 114,610 116,725
Accumulated other comprehensive loss (8,069) (7,842)
Total Pfizer Inc. shareholders’ equity 86,476 88,203
Equity attributable to noncontrolling interests 299 294
Total equity 86,775 88,497
Total liabilities and equity $ 208,160 $ 213,396
[1] As a result of the organizational changes to the commercial structure within the Biopharma operating segment effective in the first quarter of 2025 (see Note 17A), our goodwill was reallocated among impacted reporting units. We completed the re-allocation during the first quarter of 2025 and concluded that none of our goodwill was impaired. All goodwill continues to be assigned within the Biopharma reportable segment.